Array
(
[1596763926] => Array
(
[wp_update_themes] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_update_plugins] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1596764373] => Array
(
[wp_privacy_delete_old_export_files] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1596764800] => Array
(
[wordfence_hourly_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1596764881] => Array
(
[wpm_update_stats] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1596767353] => Array
(
[wp_version_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1596770273] => Array
(
[wp_session_garbage_collection] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1596781485] => Array
(
[recovery_mode_clean_expired_keys] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596784112] => Array
(
[ai1wm_storage_cleanup] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596790171] => Array
(
[wp_scheduled_auto_draft_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596795311] => Array
(
[delete_expired_transients] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596795352] => Array
(
[wpseo-reindex-links] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596797200] => Array
(
[wordfence_daily_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596807874] => Array
(
[wp_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596816424] => Array
(
[akismet_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596819411] => Array
(
[yoast_tracking] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1596981000] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[66ba68d2add5c4cdada519ad9b8d74a5] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1596981000
)
)
)
)
[1597068000] => Array
(
[wordfence_email_activity_report] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1597213490] => Array
(
[wp_site_health_scheduled_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => weekly
[args] => Array
(
)
[interval] => 604800
)
)
)
[1597240200] => Array
(
[wordfence_start_scheduled_scan] => Array
(
[df4ffa396e2271a65f97ac47f8578821] => Array
(
[schedule] =>
[args] => Array
(
[0] => 1597240200
)
)
)
)
[1601157627] => Array
(
[publish_future_post] => Array
(
[aa3f9c41dd8e97586795881a0c603b8d] => Array
(
[schedule] =>
[args] => Array
(
[0] => 472787
)
)
)
)
)
Etiquetas: ADN, Anticuerpos monoclonales, Bioequivalencia, Biofármacos, Biofármacos en España, Biosimilares, Bioterapia, Consejo general de Cólegios oficiales de farmacéuticos, DNA, España, Fármaco, Febrero 2011, Madrid, Medicamento, Medicamentos biotecnológicos, Mercado biofarmacéutico, Mercado biofarmacéutico en España, Panorama, Panorama de los biofármacos, Punto Farmacológico, salud, Sanidad.
Etiquetas: Avaluació, Barcelona, Bases per a la definició del projecte, Centre Català d´investigació i desevolupament, Collaboracions internacionals en el camp de la inmunoteràpia i vacuna, Conveni de collaboració entre Fundació Irsicaixa i Fundació Clínic, Creació de la Fundació Privada per part de la Conselleria de Salut, DEiU, Departament de Ensenyament i Universitats, Desenvolupament, Direcció del projecte, DNA, Enunciat de l’oportunitat, Estat actual de desenvolupament de la vacuna contra la SIDA., Finalitat del projecte, Fites, Formulació de l’oportunitat, Fundació Irisicaixa, Fundació Irsicaixa i Fundació Clinic, Gestió del projecte, Hivacat, Hospital Clínic de Barcelona, Hospital Germans Trias i Pujol, Material fungible, Material inventariable, ORVACS, Personal científic, Personal de Direcció i Gestió, Pla funcional, Planificació, Previsions econòmiques, Programació de la implementació, Projectes actualment en desenvolupament o previstos, Proposta de resposta a l’oportunitat, Recursos físics, Recursos humans, Recursos instrumentals, Resultats esperables i impacte de HIVACAT, Resultats esperables i impacte d’HIVACAT, salud, Sanidad, Sanitat, Sida, Vacuna Profilàctica, Vacuna Terapéutica, Vacunes per la sida, Vacunes terapèutiques, VIH.
.gif)